Surgically Targeted Radiation Therapy (STaRT) for Brain Tumors
GT Medical Technologies announced today that it has earned the International Organization for Standardization (ISO) 13485:2016 certification from GMED. The certification demonstrates the company’s compliance with medical device quality management system requirements under the Medical Device Single Audit Program (MDSAP).
GT has a number of advantages. Unlike with traditional brachytherapy, the collagen tile provides a buffer around the radiation sources, allowing delivery of the optimal radiation dose while preserving healthy tissue.
GT Medical Technologies Inc., creators of GammaTile Therapy, a Surgically Targeted Radiation Treatment for operable brain tumors, today announced its 2021 roster of ELITE Distinguished Brain Tumor Specialists that have completed 10 or more GammaTile Therapy procedures in 2021.
Saint Alphonsus doctors are now the first in the Northwest to use GammaTile–a radiation therapy treatment for brain tumors.
The FDA-cleared treatment surgically implants postage-stamp-sized tiles which provide radiation over the course of 33 days and then disintegrate.
Drs. Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor.
Mayfield Brain & Spine’s Vincent DiNapoli, M.D., Ph.D. was the first surgeon in the eastern U.S. to perform surgery on recurrent brain tumors using a new radiation delivery technique called GammaTile Therapy. Now, he’s partnered with Oncology Hematology Care and Jewish Hospital – Mercy Health (where he’s also the director of the Brain Tumor Center) for a new study using GammaTile to treat newly diagnosed primary cancer that’s moved to the brain. DiNapoli explains how the treatment works.
A cancer patient at Henry Ford with a recurring brain tumor is the first person in Michigan to receive an implanted device as treatment.
41-year-old Thomas Groves II from St. Clair received surgically targeted radiation therapy called GammaTile Therapy. Groves said he hopes this can lead to a medical breakthrough ultimately helping many.
Surgeons at Henry Ford Health System have treated a patient with a recurrent brain tumor by delivering a dose of radiation directly to the cancer inside the brain, a novel approach that could delay or prevent future tumor cells from regrowing.
Mayfield Brain & Spine, the region’s premier neurosurgery practice, announced that the first patients have been enrolled in a new clinical trial to investigate GammaTile® targeted therapy to treat newly diagnosed metastatic brain tumors.
During these uncertain times, remember to proactively reach out to patients and encourage them to resume routine cancer screenings to prevent delayed diagnoses that might lead to worsened health outcomes.